Chewy’s Q2 Was Better Than the Stock Reaction — but JPMorgan’s Downgrade Highlights Organic Growth Risk

Chewy’s second-quarter results were fundamentally solid, but the market is focusing on a different question: how fast can the business grow when the broader pet category remains pressured?

Chewy reported fiscal second-quarter 2026 net sales of $3.33 billion, up 7.3% year over year. Excluding contributions from SmartPak and Modern Animal, growth was 5.7%. Gross margin held at 30.4%, adjusted EBITDA rose to $226.7 million and adjusted EBITDA margin improved 90 basis points to 6.8%.

Management characterized the quarter as strong and raised its full-year revenue and profitability outlook. Those are not the numbers of a company experiencing an operating breakdown.

The downgrade from JPMorgan therefore matters because it attacks the growth quality rather than the execution. The source material says JPMorgan moved Chewy to Neutral from Overweight and reduced its price target to $24, citing macroeconomic pressure on organic growth and weakness in discretionary and premium pet categories.

That distinction is important. A retailer can execute well, gain share and expand margins while still delivering a disappointing stock return if the end market grows slowly and expectations were higher.

Chewy has structural strengths. Autoship creates a recurring-revenue component, customer retention remains important, and the company continues expanding into services such as veterinary care. Those characteristics can reduce volatility relative to a pure discretionary retailer.

The concern is that acquisitions and new businesses can make headline growth look stronger than the underlying core. Investors should therefore pay close attention to organic sales growth, active customer trends and net sales per active customer rather than focusing only on consolidated revenue.

Margin quality is another area to watch. The source article notes that part of the recent margin outperformance benefited from timing-related items, including a tariff refund. That does not make the quarter weak, but it means investors should separate recurring operating improvement from discrete benefits.

Free cash flow also matters because Chewy is investing in growth initiatives. A company can produce higher adjusted EBITDA while still disappointing on cash conversion if working capital, capital expenditures or investment needs rise.

The bull case is that Chewy continues gaining share in a resilient category, converts recurring customer relationships into higher lifetime value and uses scale to improve margins. The bear case is that pet spending remains sluggish enough that growth slows even while the company executes well.

The downgrade does not change company guidance. It represents an analyst’s view that the risk-reward is less attractive at current expectations. Investors should treat it as one input, not as new operating data.

The next useful evidence will come from organic growth, customer retention, Autoship penetration, veterinary-services adoption and free-cash-flow conversion. If those metrics strengthen while margins remain durable, the market may eventually look through near-term category weakness.

Chewy’s recurring model also creates an important contrast with traditional specialty retail. Pet food, medications and routine supplies are repeat purchases, which can make customer retention more valuable than a one-time sales spike. The company’s opportunity is to deepen that relationship through Autoship, pharmacy and veterinary services while keeping customer-acquisition costs disciplined. If those services raise lifetime value without requiring excessive promotional spending, slower category growth can still produce attractive economics. If they require sustained discounting, the margin story becomes less compelling.

Management’s decision to raise guidance also sets a higher bar. Once a company increases its outlook, investors begin measuring subsequent quarters against that stronger baseline. Chewy therefore needs not only to meet the new range but also to show that the drivers are repeatable. Organic growth and free cash flow will be more informative than another small adjusted-EBITDA beat if the beat depends on temporary items.

BTI’s bottom line: Chewy’s Q2 showed improving profitability and continued revenue growth, but the stock is being judged on the quality and durability of that growth. JPMorgan’s downgrade highlights the right issue: execution is not enough if the underlying category remains too weak to support the growth investors are paying for.